Arsenic trioxide: insights into its evolution to an anticancer agent
- 2 February 2018
- journal article
- review article
- Published by Springer Science and Business Media LLC in JBIC Journal of Biological Inorganic Chemistry
- Vol. 23 (3), 313-329
- https://doi.org/10.1007/s00775-018-1537-9
Abstract
Arsenic and its various forms have been in use in ancient Chinese medicine for more than 2000 years. Arsenicals have gained importance for having remedial effects for various diseases from syphilis to cancer thus highlighting its role as a therapeutic agent even though it has been labelled as a potential ‘poison’. The ability of arsenic, specifically arsenic trioxide, to treat acute promyelocytic leukaemia has radically changed the perception of this poison and has been the main factor for the re-emergence of this candidate to Western medicine for the treatment of leukaemia and other solid tumours. This review highlights the glorious history of arsenic and its various forms with major emphasis on arsenic trioxide as a therapeutic agent. The mechanism of action, pathogenesis, pharmacokinetic profile, safety concerns, ongoing clinical trials and various new forms of arsenic trioxide are discussed. The review also outlines the therapeutic ability of this drug, discusses the latest developments and recent investigations and potential advancement of arsenic trioxide as nanoformulations that has made it emerge as a potential remedial agent.Keywords
Funding Information
- University Grants Commission (MANF-2014-15-SIK-MAH-37834)
This publication has 138 references indexed in Scilit:
- Synthesis and Biological Evaluation of Novel Folic Acid Receptor-Targeted, β-Cyclodextrin-Based Drug Complexes for Cancer TreatmentPLOS ONE, 2013
- Molecular mechanism of pancreatic tumor metastasis inhibition by Gd@C 82 (OH) 22 and its implication for de novo design of nanomedicineProceedings of the National Academy of Sciences of the United States of America, 2012
- Targeting metabolism with arsenic trioxide and dichloroacetate in breast cancer cellsMolecular Cancer, 2011
- Arsenic Exposure and Toxicology: A Historical PerspectiveToxicological Sciences, 2011
- MicroRNA-148b is frequently down-regulated in gastric cancer and acts as a tumor suppressor by inhibiting cell proliferationMolecular Cancer, 2011
- Arsenic trioxide — An old drug rediscoveredBlood Reviews, 2010
- A Novel Nanoparticulate Formulation of Arsenic Trioxide with Enhanced Therapeutic Efficacy in a Murine Model of Breast CancerClinical Cancer Research, 2010
- The conformation change of Bcl-2 is involved in arsenic trioxide-induced apoptosis and inhibition of proliferation in SGC7901 human gastric cancer cellsWorld Journal of Surgical Oncology, 2010
- Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxideMolecular Cancer Therapeutics, 2009
- Magnetic nanoparticles in MR imaging and drug deliveryAdvanced Drug Delivery Reviews, 2008